Drug Shortages Turn Healthcare Supply Chains Into a Strategic Priority

Medicine shortages were once treated as an occasional procurement headache — a product that ran dry for a few weeks before normal service resumed. That assumption is increasingly difficult to sustain. Shortages now touch injectable generics, oncology agents, antibiotics, sterile fluids, anaesthetics and paediatric formulations, and they recur across markets rather than resolving cleanly. For hospitals, clinics and the manufacturers that supply them, the result is a shift in status: supply continuity is moving from an operational detail handled deep inside the procurement function to a board-level resilience question.

The change matters because shortages do not simply inconvenience purchasing departments. They alter clinical decisions, consume pharmacist and nursing time, and can delay or modify treatment. That is why supply-chain resilience is becoming part of healthcare governance and operational excellence — a theme that sits close to the concerns recognised through the Global Healthcare Awards.

Why shortages have become a board-level risk

The clinical consequences of a missing product are rarely confined to the pharmacy. When a medicine is unavailable, clinicians may need to substitute an alternative agent, adjust dosing, monitor patients more closely for the effects of an unfamiliar product, or postpone procedures that depend on a specific drug or sterile preparation.

Those decisions carry risk. Substitutions are not always clinically equivalent, and they can introduce new safety considerations around dosing, administration routes and interactions. Shortages of sterile fluids or anaesthetic agents can affect theatre scheduling. Shortages of paediatric formulations can leave clinicians improvising with adult presentations, which adds preparation steps and error potential.

The operational burden is equally significant. Pharmacy teams spend substantial time locating stock, negotiating with distributors, checking alternative suppliers and communicating with wards. Procurement teams move from planned contracting to reactive spot purchasing, often at higher cost and with less certainty about quality and provenance. Repeated disruption erodes confidence among clinical staff and can create friction between departments that are each managing their own scarcity.

At board level, these are no longer isolated incidents. They are recurring exposures that affect patient safety, financial forecasting, contractual obligations and, in some cases, regulatory compliance. That combination is what turns a procurement problem into a governance one.

Mapping critical dependencies

The first practical step for any provider is to understand where it is exposed. Most organisations purchase thousands of line items, but only a subset is genuinely critical: products with no ready substitute, products used in time-sensitive care, and products where a single supplier or single manufacturing site serves the entire market.

A useful dependency review typically asks several questions of each critical medicine:

• Is the product single-source, or does it depend on one manufacturing site or one active pharmaceutical ingredient supplier?
• Is manufacturing geographically concentrated in a region exposed to a common risk?
• How easily can the product be substituted clinically, and what would substitution require in terms of training, monitoring or reformulation?
• What is the realistic lead time for alternative supply, and how much buffer stock would cover that gap?
• Which clinical services would be affected first if supply stopped?

This is a different lens from spend analysis. A low-cost injectable used in emergency care may represent a far greater resilience risk than a high-value product with multiple suppliers and ready alternatives. Mapping should therefore be led jointly by pharmacy, procurement and clinical leadership rather than by purchasing alone, and it should be refreshed as contracts, suppliers and clinical pathways change.

Building shortage-response playbooks

When a shortage hits, the quality of the response depends largely on decisions made before it began. Providers that manage disruption well tend to work from a pre-agreed playbook rather than assembling a response in real time.

Such a playbook commonly sets out who convenes the response, how information is verified, and at what point escalation occurs. It defines the roles of clinicians, pharmacists, procurement teams, quality and regulatory affairs, and communications. It also pre-approves, where clinically appropriate, substitution and conservation protocols so that frontline staff are not negotiating therapeutic alternatives under pressure.

Conservation deserves particular attention. Simple measures — restricting use to defined indications, standardising order sets, adjusting preparation and dosing where evidence supports it, and reviewing wastage — can extend available stock considerably. Equally important is a clear position on prioritisation: which patient groups or services receive available stock first, and on what clinical and ethical basis.

Regulatory routes also belong in the playbook. Many jurisdictions allow expedited approvals, unlicensed import or temporary flexibility during confirmed shortages, but these mechanisms have conditions and timelines that are easier to navigate when the process is already understood. Communication templates for staff, patients and, where relevant, commissioners or payers reduce the risk of inconsistent messaging.

Better data, earlier warnings and diversified sourcing

Visibility is the foundation of any resilience strategy. Regulators in several major markets now publish shortage information and require manufacturers to notify them of anticipated supply problems, while professional bodies maintain their own tracking. These sources are useful but rarely sufficient on their own, because they describe a shortage once it exists rather than predicting it.

Providers can strengthen their own early warning by monitoring consumption patterns, back-order data and distributor allocations, and by sharing that intelligence within regional purchasing collaborations. Group purchasing arrangements and peer networks allow organisations to detect a problem before it reaches every pharmacy individually.

Supplier diversification is the complementary move. Dual sourcing for critical items, qualification of alternative manufacturers, and carefully judged buffer stock can reduce the impact of a single failure. Each carries trade-offs: additional suppliers mean additional qualification and quality oversight, while buffer stock ties up capital and risks expiry. The right balance depends on the clinical criticality of the product and the realistic lead time for alternatives.

Transparency matters here too. Knowing who actually makes a product — including sub-tier ingredient suppliers — is increasingly part of responsible purchasing, because a supplier's own supply base may be more concentrated than its customer list suggests.

Conclusion

Drug shortages are unlikely to disappear. Globalised manufacturing, concentrated production of certain ingredients and limited redundancy in generic markets all point to continuing volatility. The organisations that cope best will be those that treat supply continuity as a measurable part of healthcare quality rather than an unlucky exception.

That means assigning clear ownership, reviewing critical dependencies on a regular cycle, testing shortage playbooks before they are needed, and reporting resilience indicators to the board alongside financial and clinical performance. For providers and manufacturers alike, the strategic question is no longer whether shortages will occur, but how quickly and safely an organisation can respond when they do.